total hip arthroplasty. Presence of orthopedic joint implants
Conditions
Interventions
Intervention 1: Administration of 16 mg intravenous dexamethasone (manufactured by Raha Pharmaceutical Company) 30 minutes before anesthesia. Intervention 2: Administration of placebo consisting of in
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients undergoing primary hip arthroplasty
Exclusion criteria
Exclusion criteria: Previous hip surgery history High riding DDH including Crowe type III, IV Diabetes mellitus or any medical condition with contraindication to dexamethasone administration THR following acute hip fx People with drug abuse or long-term use of opioid drugs before surgery Women during lactation or pregnancy People with kidney or liver failure People with allergies or drug sensitivity to corticosteroids or pregabalin and acetaminophen Patients who do not consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome includes assessment of postoperative pain intensity, time to first ambulation, walking distance on the morning following surgery, and pain severity during ambulation and at rest. Timepoint: The aim of this study is to assess postoperative pain intensity using the Visual Analog Scale (VAS) at 12, 24, and 48 hours after surgery, both at rest and during ambulation within the hospital setting. Method of measurement: Visual Analog Scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Opioid consumption (number of pethidine injections and total dose administered based on patient request for pain control). Timepoint: The outcome assessment period will span from the time of surgery until the patient's discharge from the hospital. Method of measurement: Information related to opioid consumption will be assessed by the principal investigator during regular 12-hour interval visits and recorded in the corresponding questionnaire.;Incidence of postoperative nausea and vomiting (number of antiemetic injections administered based on patient symptoms). Timepoint: The outcome assessment period will span from the time of surgery until the patient's discharge from the hospital. Method of measurement: Information regarding the severity of nausea and vomiting, as well as the dosage of administered antiemetic medication, will be assessed by the principal investigator during scheduled 12-hour interval visits and recorded in the designated questionnaire.;Occurrence of confusion and agitation following opioid administration. Timepoint: The outcome assessment period will span from the time of surgery until the patient's discharge from the hospital. Method of measurement: Information related to drug side effects and patient symptoms, including dizziness and agitation, will be assessed by the principal investigator during regular 12-hour interval visits and documented in the corresponding questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSadegh Asadi
Iran University of Medical Sciences
Outcome results
None listed